CoChat

Long Leukocyte Telomere Length at Diagnosis Is a Risk Factor for Dementia Progression in Idiopathic Parkinsonism

Open access
Degerman, Sofie, Domellöf, Magdalena, Landfors, Mattias, Linder, Jan, Lundin, Mathias, Haraldsson, Susann, Elgh, Eva, Roos, Göran, Forsgren, Lars · 2014 · PLoS ONE
Cited by 32

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Telomere length (TL) is regarded as a marker of cellular aging due to the gradual shortening by each cell division, but is influenced by a number of factors including oxidative stress and inflammation. Parkinson's disease and atypical forms of parkinsonism occur mainly in the elderly, with oxidative stress and inflammation in afflicted cells. In this study the relationship between blood TL and prognosis of 168 patients with idiopathic parkinsonism (136 Parkinson's disease [PD], 17 Progressive Supranuclear Palsy [PSP], and 15 Multiple System Atrophy [MSA]) and 30 controls was investigated. TL and motor and cognitive performance were assessed at baseline (diagnosis) and repeatedly up to three to five years follow up. No difference in TL between controls and patients was shown at baseline, nor any significant difference in TL stability or attrition during follow up. Interestingly, a significant relationship between TL at diagnosis and cognitive phenotype at follow up in PD and PSP patients was found, with longer mean TL at diagnosis in patients that developed dementia within three years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0113387

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 24

  1. L Kaszubowska, 2008, Telomere shortening and ageing of the immune system, J Physiol Pharmacol, 59, 169
  2. AH Schapira, 2011, Etiology and pathogenesis of Parkinson's disease, Mov Disord, 26, 1049, 10.1002/mds.23732 · DOI · Paper page
  3. Z Cai, 2013, Telomere shortening and Alzheimer's disease, Neuromolecular Med, 15, 25, 10.1007/s12017-012-8207-9 · DOI
  4. T Maeda, 2009, Aging-associated alteration of subtelomeric methylation in Parkinson's disease, J Gerontol A Biol Sci Med Sci, 64, 949, 10.1093/gerona/glp070 · DOI
  5. T Maeda, 2012, Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease, J Neurogenet, 26, 245, 10.3109/01677063.2011.651665 · DOI
  6. G Watfa, 2011, Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease, J Nutr Health Aging, 15, 277, 10.1007/s12603-010-0275-7 · DOI
  7. J Eerola, 2010, No evidence for shorter leukocyte telomere length in Parkinson's disease patients, J Gerontol A Biol Sci Med Sci, 65, 1181, 10.1093/gerona/glq125 · DOI
  8. H Wang, 2008, Telomere length and risk of Parkinson's disease, Mov Disord, 23, 302, 10.1002/mds.21867 · DOI · Paper page
  9. M Schurks, 2014, Telomere length and Parkinson's disease in men: a nested case-control study, Eur J Neurol, 21, 93, 10.1111/ene.12252 · DOI
  10. G Hudson, 2011, No evidence of substantia nigra telomere shortening in Parkinson's disease, Neurobiol Aging, 32, e2103
  11. JL Sanders, 2013, Telomere Length in Epidemiology: A Biomarker of Aging, Age-Related Disease, Both, or Neither, Epidemiol Rev, 35, 112, 10.1093/epirev/mxs008 · DOI · Paper page
  12. WR Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745 · DOI · Paper page
  13. I Litvan, 1996, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop, Neurology, 47, 1, 10.1212/WNL.47.1.1 · DOI · Paper page
  14. S Gilman, 1999, Consensus statement on the diagnosis of multiple system atrophy, J Neurol Sci, 163, 94, 10.1016/S0022-510X(98)00304-9 · DOI · Paper page
  15. CG Goetz, 2004, Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations, Mov Disord, 19, 1020, 10.1002/mds.20213 · DOI · Paper page
  16. M Emre, 2007, Clinical features, pathophysiology and treatment of dementia associated with Parkinson's disease, Handb Clin Neurol, 83, 401, 10.1016/S0072-9752(07)83018-1 · DOI
  17. RM Cawthon, 2002, Telomere measurement by quantitative PCR, Nucleic Acids Res, 30, e47, 10.1093/nar/30.10.e47 · DOI · Paper page
  18. JZ Guan, 2008, A percentage analysis of the telomere length in Parkinson's disease patients, J Gerontol A Biol Sci Med Sci, 63, 467, 10.1093/gerona/63.5.467 · DOI
  19. K Nordfjall, 2009, The individual blood cell telomere attrition rate is telomere length dependent, PLoS Genet, 5, e1000375, 10.1371/journal.pgen.1000375 · DOI · Paper page
  20. U Svenson, 2013, Telomere length in relation to immunological parameters in patients with renal cell carcinoma, PLoS One, 8, e55543, 10.1371/journal.pone.0055543 · DOI
  21. AD Reynolds, 2007, Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease, J Leukoc Biol, 82, 1083, 10.1189/jlb.0507296 · DOI · Paper page
  22. D Rosenkranz, 2007, Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration, J Neuroimmunol, 188, 117, 10.1016/j.jneuroim.2007.05.011 · DOI · Paper page
  23. JA Saunders, 2012, CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease, J Neuroimmune Pharmacol, 7, 927, 10.1007/s11481-012-9402-z · DOI · Paper page
  24. HJ Lee, 2014, Extracellular alpha—synuclein-a novel and crucial factor in Lewy body diseases, Nat Rev Neurol, 10, 92, 10.1038/nrneurol.2013.275 · DOI · Paper page

Cited by

Metadata

Authors
Degerman, S., Domellöf, M., Landfors, M., Linder, J., Lundin, M., Haraldsson, S., Elgh, E., Roos, G., & Forsgren, L.
Venue
PLoS ONE
Published
2014-12-12
Volume
9
Issue
12
Pages
e113387
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2079744861
Cited by
32
References
2
FWCI
1.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.